title: [Clinical observation of DECP combination chemotherapy for relapsing and refractory multiple myeloma patients with extramedullary plasmacytomas].
abstract: OBJECTIVE
  To explore the clinical effect and toxicity of (cisplatin, etoposide, ifosfamide & dexamethasone) DECP combination chemotherapy in the treatment of relapsing and refractory multiple myeloma (MM) with extramedullary plasmacytomas.
  
  
  METHODS
  A total of 20 relapsed and refractory MM patients with extramedullary plasmacytomas treated with DECP regimen from May 2005 to May 2013 were analyzed retrospectively. DECP protocols included cisplatin 20 mg/m(2), Day 1-3; etoposide 100 mg/d,Day 1-3; ifosfamide 500 mg·m(-2)·d(-1), Day 1-4; dexamethasone 20 mg/d, Day 1-4. Efficacy was evaluated after 2 therapeutic cycles.
  
  
  RESULTS
  After 2 therapeutic cycles, the objective response rate (ORR) was 55% (11/20). After 3 therapeutic cycles, the ORR was 7/12.Seven patients completed 4 cycles with an ORR of 4/7. Two patients had finished 6 cycles and continued to maintain partial remission. The most common adverse events included gastrointestinal reaction and myelosuppression. The median follow-up time was 30 (12-80) months. The median time of overall survival (OS) was 30 (9-121) months. The 1-year OS was 73%, 2-year OS 28% and 3-year OS 21%.
  
  
  CONCLUSIONS
  The DECP chemotherapy is both effective and safe in the treatment of relapsed and refractory MM patients with extramedullary plasmacytomas.
authors.affiliation: Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100043, China.
authors.forename: Xin
authors.initials: X
authors.lastname: Li
authors.forename: Wanjun
authors.initials: W
authors.lastname: Sun
authors.forename: Fengyan
authors.initials: F
authors.lastname: Jin
authors.forename: Shilun
authors.initials: S
authors.lastname: Chen
authors.forename: Yuping
authors.initials: Y
authors.lastname: Zhong
authors.forename: Ying
authors.initials: Y
authors.lastname: Hu
authors.forename: Jiajia
authors.initials: J
authors.lastname: Zhang
authors.forename: Na
authors.initials: N
authors.lastname: An
authors.forename: Man
authors.initials: M
authors.lastname: Shen
authors.affiliation: Email: huangzhongxia@sina.com.
authors.forename: Zhongxia
authors.initials: Z
authors.lastname: Huang
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D012189:Retrospective Studies; D016896:Treatment Outcome